186 related articles for article (PubMed ID: 22801991)
1. Non-alcoholic fatty liver, adipose tissue, and the bone: a new triumvirate on the block.
Musso G
Endocrine; 2012 Oct; 42(2):237-9. PubMed ID: 22801991
[No Abstract] [Full Text] [Related]
2. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver.
Musso G; Paschetta E; Gambino R; Cassader M; Molinaro F
Trends Mol Med; 2013 Sep; 19(9):522-35. PubMed ID: 23816817
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific expression of Sprouty1 in mice protects against high-fat diet-induced fat accumulation, bone loss and metabolic dysfunction.
Urs S; Henderson T; Le P; Rosen CJ; Liaw L
Br J Nutr; 2012 Sep; 108(6):1025-33. PubMed ID: 22142492
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease.
Gaggini M; Morelli M; Buzzigoli E; DeFronzo RA; Bugianesi E; Gastaldelli A
Nutrients; 2013 May; 5(5):1544-60. PubMed ID: 23666091
[TBL] [Abstract][Full Text] [Related]
5. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis.
Filip R; Radzki RP; Bieńko M
Clin Interv Aging; 2018; 13():1879-1891. PubMed ID: 30323574
[TBL] [Abstract][Full Text] [Related]
6. JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease.
Tarantino G; Caputi A
World J Gastroenterol; 2011 Sep; 17(33):3785-94. PubMed ID: 21987620
[TBL] [Abstract][Full Text] [Related]
7. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
Caldwell SH; Ikura Y; Iezzoni JC; Liu Z
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S11-9. PubMed ID: 17567458
[TBL] [Abstract][Full Text] [Related]
8. [Obesity and bone metabolism].
Holecki M; Zahorska-Markiewicz B; Wiecek A; Nieszporek T; Zak-Gołab A
Endokrynol Pol; 2008; 59(3):218-23. PubMed ID: 18615396
[TBL] [Abstract][Full Text] [Related]
9. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
Cusi K
Gastroenterology; 2012 Apr; 142(4):711-725.e6. PubMed ID: 22326434
[TBL] [Abstract][Full Text] [Related]
10. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.
Fabbrini E; Mohammed BS; Magkos F; Korenblat KM; Patterson BW; Klein S
Gastroenterology; 2008 Feb; 134(2):424-31. PubMed ID: 18242210
[TBL] [Abstract][Full Text] [Related]
11. [Molecular mechanisms in digestive organ diseases based on accumulation of visceral fat--role of adiponectin].
Kawata S; Misawa K; Sanjo M; Otake S
Nihon Shokakibyo Gakkai Zasshi; 2005 Nov; 102(11):1384-91. PubMed ID: 16318377
[No Abstract] [Full Text] [Related]
12. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
Baranova A; Tran TP; Birerdinc A; Younossi ZM
Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
[TBL] [Abstract][Full Text] [Related]
13. The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease.
Romero-Zerbo SY; García-Fernández M; Espinosa-Jiménez V; Pozo-Morales M; Escamilla-Sánchez A; Sánchez-Salido L; Lara E; Cobo-Vuilleumier N; Rafacho A; Olveira G; Rojo-Martínez G; Gauthier BR; González-Mariscal I; Bermúdez-Silva FJ
Front Endocrinol (Lausanne); 2020; 11():103. PubMed ID: 32210914
[No Abstract] [Full Text] [Related]
14. Non-alcoholic fatty liver disease and insulin resistance.
Machado M; Cortez-Pinto H
Eur J Gastroenterol Hepatol; 2005 Aug; 17(8):823-6. PubMed ID: 16003131
[TBL] [Abstract][Full Text] [Related]
15. Adipose, bone and muscle tissues as new endocrine organs: role of reciprocal regulation for osteoporosis and obesity development.
Migliaccio S; Greco EA; Wannenes F; Donini LM; Lenzi A
Horm Mol Biol Clin Investig; 2014 Jan; 17(1):39-51. PubMed ID: 25372729
[TBL] [Abstract][Full Text] [Related]
16. Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.
Berk PD
Hepatology; 2008 Nov; 48(5):1362-76. PubMed ID: 18972439
[No Abstract] [Full Text] [Related]
17. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease.
Azzu V; Vacca M; Virtue S; Allison M; Vidal-Puig A
Gastroenterology; 2020 May; 158(7):1899-1912. PubMed ID: 32061598
[TBL] [Abstract][Full Text] [Related]
18. Macronutrients and the Adipose-Liver Axis in Obesity and Fatty Liver.
Duwaerts CC; Maher JJ
Cell Mol Gastroenterol Hepatol; 2019; 7(4):749-761. PubMed ID: 30763771
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
20. Dietary d-limonene alleviates insulin resistance and oxidative stress-induced liver injury in high-fat diet and L-NAME-treated rats.
Victor Antony Santiago J; Jayachitra J; Shenbagam M; Nalini N
Eur J Nutr; 2012 Feb; 51(1):57-68. PubMed ID: 21445622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
